Chamkouri Narges, Absalan Forouzan, Koolivand Zahra, Yousefi Mahsa
Medical Faculty, Abadan University of Medical Sciences, Abadan, Iran.
Adv Biomed Res. 2023 Jan 30;12:20. doi: 10.4103/abr.abr_148_21. eCollection 2023.
During the current SARS-CoV-2 (COVID-19) pandemic, some reports were presented based on those nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. According to this, we aimed to collate information available in published articles to identify any evidence behind these statements with the aim of helping clinicians on how best to treat patients. We could not find published conclusive evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilized in the early acute phase of infection, however, conflicting WHO (World Health Organization) evidence surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients. However, the availability of reliable information for clinicians and patients is paramount.
在当前新型冠状病毒(COVID-19)大流行期间,有一些报告指出,非甾体抗炎药(NSAIDs)和皮质类固醇可能会加重COVID-19患者的症状。据此,我们旨在整理已发表文章中的可用信息,以确定这些说法背后的任何证据,从而帮助临床医生了解如何最好地治疗患者。我们没有找到支持或反对在COVID-19患者中使用NSAIDs的已发表的确凿证据。同时,似乎有一些证据表明,如果在感染的早期急性期使用皮质类固醇可能有益,然而,世界卫生组织(WHO)关于在某些病毒感染中使用皮质类固醇的证据相互矛盾,这意味着该证据并不确凿。鉴于目前的文献情况,在出现更多关于COVID-19患者使用NSAIDs和皮质类固醇的证据之前,应谨慎行事。然而,为临床医生和患者提供可靠信息至关重要。